XAGE (Longevity Health Holdings) Current Accrued Expense: $0.95 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XAGE Longevity Health Holdings Inc XAGE
17 GF Score
Price $0.22
! 4 Warning Signs
View Full Analysis

What is Longevity Health Holdings Current Accrued Expense?

Longevity Health Holdings XAGE 17 Current Accrued Expense is $0.95 Mil as of Jun. 2026. GuruFocus rates XAGE with a GF Score™ of 17/100. The stock has 4 warning signs investors should review.

Longevity Health Holdings's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.95 Mil.

Longevity Health Holdings's quarterly Current Accrued Expense declined from Dec. 2025 ($2.22 Mil) to Mar. 2026 ($1.99 Mil) and declined from Mar. 2026 ($1.99 Mil) to Jun. 2026 ($0.95 Mil).

Longevity Health Holdings's annual Current Accrued Expense declined from Dec. 2023 ($1.48 Mil) to Dec. 2024 ($1.47 Mil) but then increased from Dec. 2024 ($1.47 Mil) to Dec. 2025 ($2.22 Mil).

Longevity Health Holdings Current Accrued Expense Related Terms

Longevity Health Holdings Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Longevity Health Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Health Holdings Current Accrued Expense Chart

Longevity Health Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
1.88 0.51 1.48 1.47 2.22

Longevity Health Holdings Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.07 2.17 2.22 1.99 0.95
XAGE
17GF Score
Longevity Health Holdings Inc XAGE
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longevity Health Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.95 Mil mean?
Longevity Health Holdings (XAGE) has a Current Accrued Expense of $0.95 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Longevity Health Holdings and its competitors.
Is Longevity Health Holdings' Current Accrued Expense too high?
Longevity Health Holdings' current Current Accrued Expense is $0.95 Mil. Overall, Longevity Health Holdings has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Longevity Health Holdings' Current Accrued Expense compare to SNBH and SKVI?
Longevity Health Holdings' Current Accrued Expense of $0.95 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Consumer Packaged Goods company?
A good Current Accrued Expense depends on the Consumer Packaged Goods industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Longevity Health Holdings and its competitors. Longevity Health Holdings's current Current Accrued Expense is $0.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Health Holdings stock overvalued right now?
Longevity Health Holdings (XAGE) has a current Current Accrued Expense of $0.95 Mil. The current Current Accrued Expense is $0.95 Mil. Longevity Health Holdings' overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Longevity Health Holdings (XAGE), the current Current Accrued Expense is $0.95 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Health Holdings Business Description

Address 2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Longevity Health Holdings Inc is a bio-aesthetics company focused on longevity and healthy aging. The company develops cosmetic skincare and haircare products designed to support skin and hair health, tailored to meet the technical requirements of professional care providers as well as retail consumers. Its product pipeline also includes regenerative bone and tissue healing solutions, although further research and development in this area has been paused. The company markets its cosmetic products in the United States through business-to-business, direct-to-consumer, and distributor sales channels.
17GF Score

Get the complete analysis for XAGE

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price